Initially developed as a neo-vasculature disrupting agent, the small molecule STING agonist DMXAA, failed to improve outcome of patients with NSCLC when co-administered with standard-of-care chemotherapy in a Phase III clinical trial despite promising results seen in preclinical murine models [67]. Here, STING1 is linked to non-small cell lung carcinoma.